CBRI yields 2000000.00% · PFE yields 6.20%● Live data
📍 CBRI pulled ahead of the other in Year 1
Combined, CBRI + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CBRI + PFE for your $10,000?
CMTSU Liquidation, Inc. operates as an information technology (IT) service company worldwide. It operates as an independent software vendor or channel partner; and provides project management, application and technical consulting, and database administration for implementation projects and managed-services. The company also offers managed services; and enterprise application, IT strategy, and business process consultancy services, as well as project planning, systems implementation and integration, training and change management, and application management. Its application development and management/staffing services provide analysis, design, development, testing and quality assurance, implementation, and maintenance of its client's business applications. In addition, the company offers staffing services covering software development lifecycle, as well as steady-state operations; and sells various IT hardware and software products. It serves Global 2000 blue-chip companies in industries, such as manufacturing, retail, education, healthcare and life sciences, energy and utilities, financial services, and the public sector. The company was formerly known as Ciber, Inc. and changed its name to CMTSU Liquidation, Inc. in June 2017. CMTSU Liquidation, Inc. was founded in 1974 and is based in Denver, Colorado. On April 9, 2017, CMTSU Liquidation, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the US Bankruptcy Court for the District of Delaware. The plan was later approved as Chapter 11 liquidation on December 20, 2018.
Full CBRI Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.